GLP-1 Medications, Ozempic, Wegovy

Key Takeaways

Researchers reviewed 48 trials with more than 94,000 adults taking GLP-1 drugs

Results found little to no effect on the risk of 13 obesity-related cancers

Experts say longer-term studies are still needed

WEDNESDAY, Dec. 10, 2025 (HealthDay News) — A new study suggests popular GLP-1 drugs, like Ozempic and Zepbound , may not lower cancer risk as some had hoped.

Researchers analyzed 48 randomized trials in

The team wanted to know whether these medications change someone’s risk of developing any of the 13 cancers linked to obesity. The results showed GLP-1 drugs had little to no effect on the risk of cancers such as breast, thyroid , pancreatic or kidney cancer.

“It’s not that GLP-1 does not reduce the risk of cancer; I don’t thin

See Full Page